Atopic Dermatitis
Conditions
Brief summary
This exploratory study aims to evaluate the impact of a cosmetic product (Lactibiane Topic AD) vs placebo on skin flora and skin reinforcement barrier in mild to moderate atopic dermatitis using biometrological, biological and clinical parameters.
Interventions
OTHERLactibiane Topic AD
Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
OTHERPlacebo
Application of placebo twice a day (morning and evening) on the symmetrical lesional area
Sponsors
PiLeJe
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subject diagnosed with mild to moderate AD defined as SCORAD≤40 (Eichenfield et al. JAAD 2014). * Subject with at least two symmetric AD lesions with comparable severity: Located either on upper extremities (left and right arms except hands) or lower extremities (left and right legs except feet), With an erythema ≥ 1 (mild to severe intensity), With a lesional area score ≥ 4 on both lesions with an authorized delta of two points between the two lesions, With a sufficient extent to allow all the investigations. * Subject with I, II, III or IV skin phototype (according to Fitzpatrick's scale). * For woman of childbearing potential (defined as all women physiologically capable of becoming pregnant): Negative urine pregnancy test at inclusion visit. Use of a highly effective method of birth control\* during the study. \* A highly effective method of birth control is defined as one which results in a low failure rate (less than 1%) when used consistently and correctly, such as implants, combined oral contraceptives, intrauterine device, double barrier methods (e.g. condom with spermicide), sexual abstinence or vasectomized partner. * Subject with health insurance coverage according to local regulation. * Subject having given his written informed consent.
Exclusion criteria
* Subject having a known hypersensitivity, allergy or contraindication to any ingredients contained within the investigational product or placebo. * Subject having exposed his skin to natural or artificial UV within 8 weeks prior to the inclusion visit or intending to expose his skin during the study. * Subject having performed phototherapy within 8 weeks prior to the inclusion visit or intending to perform phototherapy during the study. * Subject having performed another physical treatment (e.g radiotherapy…) on the investigational areas within 6 months prior to the inclusion visit or intending to perform it during the study. * Subject treated with systemic non-steroidal anti-inflammatory drugs (≥3 days) within 1 week before the inclusion visit. * Subject treated with biological immunosuppressive drugs within 12 weeks prior to the inclusion visit or intending to be treated with it during the study. * Subject treated with non-biological immunosuppressive drugs within 4 weeks prior to the inclusion visit or intending to be treated with it during the study. * Subject treated with systemic corticoids within 1 week prior to the inclusion visit or planed during the study. * Subject treated with systemic antibiotics within 7 days prior to the inclusion visit or planed during the study. * Subject having applied topical immunomodulators, non-steroidal anti-inflammatory, corticoids or antihistamines on investigational limbs within 1 weeks prior to the inclusion visit. * Subject having applied topical antibiotics or disinfectants on investigational limbs within 2 weeks prior to the inclusion visit. * Subject having applied any other topical and/or care product after the last grooming prior to the inclusion visit. * Subject having applied water or care product (except hands cleaning) within 12 hours prior to the inclusion visit. * Subject having started, modified or stopped any other treatment/product within 4 weeks prior to the inclusion visit or intending to do so during the study that according to the investigator's judgment, could interfere with study results. * Subject having significant medical condition that according to the investigator's judgment, deems inappropriate for study participation (e.g present or past malignancy, present or past skin condition…). * Subject having significant dermatological condition or sign (e.g disease, scare, abundant hairiness, tanning mark…) that according to the investigator's judgment, could limit the observations or/and interfere with the interpretations. * Subject taking part or having participated in another clinical study within 2 weeks prior to the inclusion visit. * Subject under legal guardianship or incapacitation. * Subject linguistically or psychologically unable of signing informed consent form and unable to comply with the protocol requirements according to the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in skin flora composition | from baseline (Day 0) at Day 21 | 16S rRNA sequencing, qPCR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Skin barrier status | Day 0, Day 14, Day 21 | TransEpidermal Water Loss (TEWL) |
| Patient Oriented SCORing Atopic Dermatitis | Day 0, Day 14, Day 21 | Patient Oriented SCORing Atopic Dermatitis (POSCORAD): 0 - 103 (Higher values represent a worse outcome) |
| SCORing Atopic Dermatitis | Day 0, Day 14, Day 21 | SCORing Atopic Dermatitis (SCORAD) : 0 - 103 (Higher values represent a worse outcome) |
| Clinical severity of lesional areas | Day 0, Day 14, Day 21 | Scoring of lesional area by subject and investigator : 0-18 (Higher values represent a worse outcome) |
| Manifestation of adverse local reactions | From Day 0 to Day 21 | Subjects will use a diary to document any potential adverse reactions observed after product application |
Countries
France
Outcome results
None listed